Loading organizations...
§ Private Profile · St Louis, MO, USA
Life science research tools & services for gene editing, gene expression, and bioprocessing for academic, biotech, and pharma.
Canopy Biosciences is a St. Louis, Missouri-based biotechnology company that develops research tools, reagents, and clinical services for gene editing, gene expression analysis, and bioprocessing. The firm supplies academic research institutions and major pharmaceutical companies worldwide with commercialized genetic engineering technologies, including CRISPR kits, custom cell line engineering, and multi-omics platforms like ChipCytometry. To accelerate commercialization and expand its clinical laboratory services, the company acquired international entities such as Zellkraftwerk and Core Diagnostics. The enterprise grew its global workforce to a total of 50 employees and secured multiple financing rounds from institutional investors including Ampersand Capital Partners, BioGenerator, and Kingdom Capital. Following its Series B funding, the business was acquired in 2020 by Bruker Corporation, operating today as a corporate subsidiary. Canopy Biosciences was founded in 2016 by Edward Weinstein, David Smoller, and Crystal Winkeler.
Canopy Biosciences has raised $2.4M across 1 funding round.
Canopy Biosciences has raised $2.4M in total across 1 funding round.
Canopy Biosciences has raised $2.4M in total across 1 funding round.
Canopy Biosciences's investors include Charlie Bolten, Brandon K. Mann, Greenleaf Fund, Missouri Technology Corporation, PinPoint Holdings, St. Louis Arch Angels.
Canopy Biosciences has raised $2.4M across 1 funding round. Most recently, it raised $2.4M Series A in May 2018.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| May 22, 2018 | $2.4M Series A | Charlie Bolten, Brandon K. Mann | Greenleaf Fund, Missouri Technology Corporation, Pinpoint Holdings, ST. Louis Arch Angels | Announced |